Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1996-12-11
1998-06-30
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514327, A61K 3166, A61K 31445
Patent
active
057734291
ABSTRACT:
This invention encompasses a pharmaceutical composition comprising an effective amount of alendronate salt for reducing calcium loss and an effective amount of a gastric propulsive agent, preferably cisapride, to prevent gastric reflux caused by the alendronate salt.
REFERENCES:
patent: 4705651 (1987-11-01), Staibano
patent: 4962115 (1990-10-01), Van Daele
patent: 5270365 (1993-12-01), Gertz et al.
patent: 5464632 (1995-11-01), Cousin et al.
De Groen et al. "Esophagitis Associated with the Use of Alendronate", N Engl. J. Med. 335:1016-21, 1996.
Reyntjens et al. (1986), "Development and Clinical Use of the New Gastrointestinal Prokinetic Drug Cisapride," Drug Development Research, vol. 8, pp. 251-265.
Reyntjens et al. (1984), "New Approach to Gastrointestinal Motor Dysfunction: Non-Antidopaminergic, Non-Cholinergic Stimulation with Cisapride," Current Therapeutic Reasearch, vol. 36, pp. 1029-1037.
Van Daele et al. (1986), "Synthesis of Cisapride, a Gastrointestinal Stimulant Derived From Cis-4-Amino-3-Methoxypiperidine," Drug Development Research, vol. 8, pp. 225-232.
Fuisz Technologies Ltd.
Henley III Raymond
Nolan Sandra M.
LandOfFree
Drug combination for treating calcium loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug combination for treating calcium loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug combination for treating calcium loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1859447